london euretina
retina race

Subfoveal choroidal thickness changes after intravitreal bevacizumab injection for neovascular age related macular degeneration

Session Details

Session Title: AMD III

Session Date/Time: Sunday 20/09/2015 | 11:00-13:00

Paper Time: 12:20

Venue: Athena

First Author: : C.Ünlü TURKEY

Co Author(s): :    G. Erdogan   B. Onal Gunay   E. Kardes   B. Sezgin Akcay   A. Ergin  

Abstract Details

PURPOSE:To investigate the changes in subfoveal choroidal thickness (SFCT) after intravitreal injection of bevacizumab (IVB) for neovascular age-related macular degeneration (AMD).

Setting:

Istanbul Umraniye Training and Research Hospital, Ophthalmology Department

Methods:

We assessed 21 affected eyes with neovascular AMD which were treated with 1.25 mg/0.5 ml IVB and 21 untreated fellow eyes of these 21 patients. SFCT was measured in all 42 eyes at baseline before IVB injection and at day 1, week 1 and month 1 after IVB injection by use of enhanced depth imaging optical coherence tomography (EDI OCT). Central foveal thickness (CFT) was also analysed at baseline before IVB injection and at day 1, week 1 and month 1 after IVB injection and best-corrected visual acuity (BCVA) was analysed at baseline and at final (1 month) visits. Main outcome measure was the change in SFCT in one month after treatment with IVB.

Results:

The mean age of the patients was 67.7±10.7 years. All 21 eyes treated with IVB showed a reduction in SFCT after injection. The mean SFCT in treated eyes decreased from 223.5 ± 85.3 µm at baseline to 202.7 ± 77.6 µm at day 1 (P= 0.005), 192.5 ± 68.6 µm at week 1 (P= 0.001) and 204.9 ±77.3 µm at month 1 (P= 0.042) (The change ratio was 91 % at day 1, 86 % at week 1, and 92% at month 1), whereas the mean SFCT in untreated fellow eyes changed from 210.6±63.0 µm at baseline to 207.8±73.1 µm at day 1 (P= 0.587), 202.1±75.7 µm at week 1 (P= 0.190) and 213.7±82.4 µm at month 1 (P= 0.668). The changes in SFCT in untreated fellow eyes were not significant. With IVB treatment, CFT decreased significantly from 382.0±113.3 µm at baseline to 298.5±79.1 µm at month 1 (P= 0.003) and Snellen visual acuity improved significantly (from 0.18 at baseline to 0.23 at final visit) (P ˂ 0.01).

Conclusions:

SFCT decreased significantly in neovascular AMD eyes following IVB injection. The decreasing effect of bevacizumab on choroidal thickness was highest at the first week and continued to the end of first month after injection. A parallel decrease in CFT associated the decrease in SFCT.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email: euretina@euretina.org

Privacy policyHotel Terms and Conditions Cancellation policy